Glaukos Co. (NYSE:GKOS) Shares Sold by Braidwell LP

Braidwell LP decreased its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 288,876 shares of the medical instruments supplier's stock after selling 22,740 shares during the period. Braidwell LP owned 0.52% of Glaukos worth $43,314,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. William Blair Investment Management LLC acquired a new stake in Glaukos during the fourth quarter valued at $121,390,000. Alliancebernstein L.P. lifted its position in Glaukos by 1,235.4% in the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock valued at $122,374,000 after acquiring an additional 755,035 shares during the last quarter. Norges Bank purchased a new stake in Glaukos during the 4th quarter valued at approximately $84,490,000. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Glaukos by 25.3% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock valued at $123,742,000 after buying an additional 166,677 shares in the last quarter. Finally, Voya Investment Management LLC grew its holdings in Glaukos by 266.2% in the fourth quarter. Voya Investment Management LLC now owns 200,698 shares of the medical instruments supplier's stock valued at $30,093,000 after purchasing an additional 145,890 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Price Performance

Glaukos stock traded down $0.60 during mid-day trading on Friday, reaching $89.94. 511,969 shares of the company were exchanged, compared to its average volume of 682,126. The company has a fifty day simple moving average of $94.87 and a 200-day simple moving average of $127.33. The firm has a market cap of $5.14 billion, a PE ratio of -31.34 and a beta of 0.83. Glaukos Co. has a 12 month low of $77.10 and a 12 month high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. During the same quarter in the previous year, the firm earned ($0.70) earnings per share. Glaukos's quarterly revenue was up 24.6% on a year-over-year basis. As a group, equities research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Piper Sandler dropped their price target on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a research report on Tuesday, April 15th. Truist Financial reiterated a "buy" rating and issued a $135.00 price objective (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Stephens lowered their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley decreased their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reduced their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.